Public health impact of antiviral therapy for hepatitis C in the United States

Cited in:

CrossRef

This article has been cited by:

1. 1
   Andrew H. Talal, Rositsa B. Dimova, Randy Seewald, Raymond H. Peterson, Marija Zeremski, David C. Perlman, Don C. Des Jarlais, Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment, Journal of Substance Abuse Treatment, 2012,

   CrossRef

2. 2
   Maxine M. Denniston, R. Monina Klevens, Geraldine M. McQuillan, Ruth B. Jiles, Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008, Hepatology, 2012, 55, 6

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(198K)
   • References
3. 3
   E. Degasperi, A. Aghemo, Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19,

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(45K)
   • References
4. 4
   P. O. Coffin, J. D. Scott, M. R. Golden, S. D. Sullivan, Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C, Clinical Infectious Diseases, 2012, 54, 9, 1259

   CrossRef

5. You have free access to this content5
   Stevan A. Gonzalez, Gary L. Davis, Demographics of hepatitis C virus today, Clinical Liver Disease, 2012, 1, 1

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(934K)
   • References
6. 6
   Lisa J. McGarry, Vivek S. Pawar, Hemangi R. Panchmatia, Jaime L. Rubin, Gary L. Davis, Zobair M. Younossi, James C. Capretta, Michael J. O'Grady, Milton C. Weinstein, Economic model of a birth cohort screening program for hepatitis C virus, Hepatology, 2012, 55, 5

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(1006K)
   • References
7. 7
   Massimo Colombo, Editorial, Journal of Viral Hepatitis, 2012, 19,

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(36K)
   • References
8. 8
   A. D. Martinez, R. Dimova, K. M. Marks, A. B. Beeder, M. Zeremski, M. J. Kreek, A. H. Talal, Integrated internist – addiction medicine – hepatology model for hepatitis C management for individuals on methadone maintenance, Journal of Viral Hepatitis, 2012, 19, 1

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(141K)
   • References
9. 9
   Amit G. Singal, Jorge A. Marrero, Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C, Digestive Diseases and Sciences, 2012, 57, 4, 832

   CrossRef

10. 10
    S. Deuffic-Burban, Y. Yazdanpanah, It Is Time to Change the Paradigm for Hepatitis C Virus Testing, Clinical Infectious Diseases, 2012, 54, 9, 1272

    CrossRef

11. 11
    Alain H. Litwin, Bryce D. Smith, Mari-Lynn Drainoni, Diane McKee, Allen L. Gifford, Elisa Koppelman, Cindy L. Christiansen, Cindy M. Weinbaum, William N. Southern, Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk, Digestive and Liver Disease, 2012, 44, 6, 497

    CrossRef

12. 12
    Brian L Pearlman, Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care, The Lancet Infectious Diseases, 2012,

    CrossRef

13. 13
    Lisa Maher, Tackling hepatitis C in Australia: the third national strategy, The Lancet Infectious Diseases, 2012, 12, 3, 172

    CrossRef

14. 14
    Jason E. Bonner, A. Sidney Barritt, Michael W. Fried, Donna M. Evon, Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C, Digestive Diseases and Sciences, 2012, 57, 6, 1439

    CrossRef

15. 15
    Karly S Louie, Samantha St Laurent, Ulla M Forssen, Linda M Mundy, Jeanne M Pimenta, The high comorbidity burden of the hepatitis C virus infected population in the United States, BMC Infectious Diseases, 2012, 12, 1, 86

    CrossRef

16. 16
    Jason E. Bonner, A. Sidney Barritt, Michael W. Fried, Donna M. Evon, Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues, Digestive Diseases and Sciences, 2012, 57, 6, 1469

    CrossRef

17. 17
    Benoît Callendret, Christopher M. Walker, Will There Be a Vaccine to Protect Against the Hepatitis C Virus?, Gastroenterology, 2012, 142, 6, 1384

    CrossRef

18. 18
    Donna M Evon, Kelly Simpson, Scott Kixmiller, Joseph Galanko, Karen Dougherty, Carol Golin, Michael W Fried, A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment, The American Journal of Gastroenterology, 2011, 106, 10, 1777

    CrossRef

19. 19
    Jason Grebely, Gregory J. Dore, An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community, Hepatology, 2011, 54, 6

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(1610K)
    • References
20. 20
    Ann D Kwong, Robert S Kauffman, Patricia Hurter, Peter Mueller, Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus, Nature Biotechnology, 2011, 29, 11, 993

    CrossRef

21. 21
    B. D. Smith, J. Drobeniuc, A. Jewett, B. M. Branson, R. S. Garfein, E. Teshale, S. Kamili, C. M. Weinbaum, Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus, Journal of Infectious Diseases, 2011, 204, 6, 825

    CrossRef

22. 22
    J. Grebely, J. Bryant, P. Hull, M. Hopwood, Y. Lavis, G. J. Dore, C. Treloar, Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia, Journal of Viral Hepatitis, 2011, 18, 4

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(119K)
    • References
23. 23
    Catherine Rongey, Hal F. Yee, From the bedside to the community: Comparative effectiveness, health services, and implementation research, Hepatology, 2011, 53, 2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(93K)
    • References
24. 24
    W. N. Southern, M.-L. Drainoni, B. D. Smith, C. L. Christiansen, D. McKee, A. L. Gifford, C. M. Weinbaum, D. Thompson, E. Koppelman, S. Maher, A. H. Litwin, Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting, Journal of Viral Hepatitis, 2011, 18, 7

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(64K)
    • References
25. 25
    K. Krauskopf, T. G. McGinn, A. D. Federman, E. A. Halm, H. Leventhal, L. K. McGinn, D. Gardenier, A. Oster, I. M. Kronish, HIV and HCV health beliefs in an inner-city community, Journal of Viral Hepatitis, 2011, 18, 11

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(62K)
    • References
26. 26
    Maria Stepanova, Fasiha Kanwal, Hashem B. El-Serag, Zobair M. Younossi, Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States, Hepatology, 2011, 53, 3

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(128K)
    • References
27. 27
    Rebecca L Morgan, Bryce D Smith, Geoff A Beckett, News from the CDC: Translating science into HCV infection screening recommendations, Translational Behavioral Medicine, 2011, 1, 4, 509

    CrossRef

28. 28
    Sanjeev Arora, Karla Thornton, Glen Murata, Paulina Deming, Summers Kalishman, Denise Dion, Brooke Parish, Thomas Burke, Wesley Pak, Jeffrey Dunkelberg, Martin Kistin, John Brown, Steven Jenkusky, Miriam Komaromy, Clifford Qualls, Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers, New England Journal of Medicine, 2011, 364, 23, 2199

    CrossRef

29. 29
    A. Probst, T. Dang, M. Bochud, M. Egger, F. Negro, P.-Y. Bochud, Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis, Journal of Viral Hepatitis, 2011, 18, 11

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(186K)
    • References
30. 30
    A. D. Branch, C. M. Rice, Antisense Gets a Grip on miR-122 in Chimpanzees, Science Translational Medicine, 2010, 2, 13, 13ps1

    CrossRef

31. 31
    M. L. Volk, Antiviral therapy for hepatitis C: why are so few patients being treated?, Journal of Antimicrobial Chemotherapy, 2010, 65, 7, 1327

    CrossRef

32. 32
    Lisa Maher, Bethany White, Margaret Hellard, Annie Madden, Maria Prins, Thomas Kerr, Kimberly Page, Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities, Vaccine, 2010, 28, 45, 7273

    CrossRef

33. 33
    David L Thomas, Curing hepatitis C with pills: a step toward global control, The Lancet, 2010, 376, 9751, 1441

    CrossRef

34. 34
    Lucy Golden-Mason, Andrea L. Cox, Jessica A. Randall, Linling Cheng, Hugo R. Rosen, Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro, Hepatology, 2010, 52, 5

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(454K)
    • References
35. 35
    Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco Negro, Christian Trépo, Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection, Clinical Gastroenterology and Hepatology, 2010, 8, 11, 924

    CrossRef

36. 36
    Kenneth Kar-Lung Yan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital, Digestive Diseases and Sciences, 2010, 55, 12, 3541

    CrossRef